IL157389A0 - A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament - Google Patents

A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament

Info

Publication number: IL157389A0
Authority: IL; Israel
Prior art keywords: bicalutamide; medicament; pharmaceutical formulation; enteric polymer; enteric
Prior art date: 2001-02-27

Application number

IL15738902A

Other languages

English (en)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2002-02-22

Publication date

2004-05-12

2001-02-27 Priority claimed from GB0104749A external-priority patent/GB2372444A/en

2001-07-19 Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx

2002-02-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-05-12 Publication of IL157389A0 publication Critical patent/IL157389A0/xx

Links

LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 title 1
229960000997 bicalutamide Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229920000642 polymer Polymers 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL15738902A 2001-02-27 2002-02-22 A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament IL157389A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0104749A GB2372444A (en)	2001-02-27	2001-02-27	A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv)	2001-07-19	2001-07-19	Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (en)	2001-02-27	2002-02-22	Pharmaceutical formulation comprising bicalutamide

Publications (1)

Publication Number	Publication Date
IL157389A0 true IL157389A0 (en)	2004-05-12

Family

ID=26245766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15738902A IL157389A0 (en)	2001-02-27	2002-02-22	A pharmaceutical formulation comprising bicalutamide and an enteric polymer and use thereof as a medicament

Country Status (22)

Country	Link
US (1)	US20040067257A1 (cs)
EP (1)	EP1368001B1 (cs)
JP (2)	JP3548566B2 (cs)
KR (1)	KR20030077042A (cs)
CN (1)	CN1503662A (cs)
AR (1)	AR032912A1 (cs)
AT (1)	ATE307571T1 (cs)
CA (1)	CA2439366A1 (cs)
CZ (1)	CZ20032225A3 (cs)
DE (1)	DE60206889T2 (cs)
EE (1)	EE200300416A (cs)
HU (1)	HUP0302847A3 (cs)
IL (1)	IL157389A0 (cs)
IS (1)	IS6915A (cs)
MX (1)	MXPA03007641A (cs)
NO (1)	NO20033785L (cs)
NZ (1)	NZ527532A (cs)
PL (1)	PL365746A1 (cs)
RU (1)	RU2003128971A (cs)
SK (1)	SK10722003A3 (cs)
UY (1)	UY27186A1 (cs)
WO (1)	WO2002067893A2 (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
TWI355276B (en) *	2003-01-14	2012-01-01	Akira Tsuji	Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
US20080138437A1 (en) *	2004-02-09	2008-06-12	Shuji Sakuma	Antitumor Agent
KR100539706B1 (ko) *	2005-01-25	2005-12-28	지엘팜텍 주식회사	타크로리무스 및 장용성 고분자를 함유하는 고체분산체
WO2006090129A2 (en) *	2005-02-23	2006-08-31	Astrazeneca Ab	Bicalutamide for delivering increasing steady state plasma levels
EP1872798B1 (en)	2005-04-06	2013-06-05	Kabushiki Kaisha Sangi	Intestinal absorptive anti-tumor agent
US7785629B2 (en) *	2005-06-21	2010-08-31	Helm Ag	Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) *	2006-06-16	2012-10-17	トーアエイヨー株式会社	腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) *	2006-08-17	2008-02-21	Gawande Rahul S	Bicalutamide compositions
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010533729A (ja)	2007-07-17	2010-10-28	プレキシコン，インコーポレーテッド	キナーゼ調節のための化合物と方法、及びそのための適応
EP2191830A4 (en)	2007-09-21	2011-11-23	Shionogi & Co	SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
JP5204452B2 (ja) *	2007-10-02	2013-06-05	日医工株式会社	ビカルタミド含有製剤
EP2219624A2 (en) *	2007-11-08	2010-08-25	Glaxo Group Limited	Pharmaceutical formulations
CA2738573C (en) *	2009-04-03	2013-02-19	F. Hoffmann-La Roche Ag	Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
CN101987086B (zh) *	2009-08-03	2012-07-18	北京化工大学	一种超细比卡鲁胺口服片剂及其制备方法
JP2013510166A (ja)	2009-11-06	2013-03-21	プレキシコンインコーポレーテッド	キナーゼ調節のための化合物、方法およびその適用
CN102892411B (zh)	2009-12-18	2015-01-21	恩多提斯药业公司	含有合成的低聚糖的药物口服剂型
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) *	2010-12-20	2013-11-20	西安力邦医药科技有限责任公司	拉米夫定固体分散体、其制备方法、药物组合物和用途
PE20141360A1 (es)	2011-02-07	2014-10-13	Plexxikon Inc	Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
TWI673051B (zh)	2012-09-11	2019-10-01	美商梅維森前列腺療法有限責任公司	恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
US9545407B2 (en) *	2014-08-07	2017-01-17	Pharmacyclics Llc	Formulations of a bruton's tyrosine kinase inhibitor
RS62421B1 (sr)	2014-12-05	2021-10-29	Aragon Pharmaceuticals Inc	Anti-kancerogeni sastavi
CN114886852A (zh)	2014-12-05	2022-08-12	阿拉贡药品公司	抗癌组合物
DK3556354T3 (da) *	2016-12-15	2025-08-04	Hua Medicine Shanghai Ltd	Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf
SG11202111251SA (en)	2019-04-11	2021-11-29	R P Scherer Technologies Llc	Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
GB2584341B (en) *	2019-05-31	2023-03-01	Gw Res Ltd	Cannabinoid formulations
US11173291B2 (en) *	2020-03-20	2021-11-16	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery
CA3171976A1 (en)	2020-03-20	2021-09-23	Carlos Schuler	Implantable drug delivery devices for localized drug delivery
US11344526B2 (en)	2020-03-20	2022-05-31	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3372965D1 (en) *	1982-07-23	1987-09-17	Ici Plc	Amide derivatives
ES2111065T5 (es) *	1991-04-16	2005-06-16	Nippon Shinyaku Company, Limited	Procedimiento para producir una dispersion solida.
CA2181358A1 (en) *	1994-01-21	1995-07-27	Nancy M. Gray	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US20030059471A1 (en) *	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
CZ20032647A3 (cs) *	2001-04-02	2004-09-15	Astrazeneca Ab	Pevná farmaceutická kompozice obsahující 4-kyanotrifluor-3-(4-fluorfenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidin a PVP
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103839D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product

2002
- 2002-02-22 CZ CZ20032225A patent/CZ20032225A3/cs unknown
- 2002-02-22 CN CNA028087356A patent/CN1503662A/zh active Pending
- 2002-02-22 CA CA002439366A patent/CA2439366A1/en not_active Abandoned
- 2002-02-22 EP EP02712105A patent/EP1368001B1/en not_active Expired - Lifetime
- 2002-02-22 DE DE60206889T patent/DE60206889T2/de not_active Expired - Fee Related
- 2002-02-22 MX MXPA03007641A patent/MXPA03007641A/es unknown
- 2002-02-22 JP JP2002567261A patent/JP3548566B2/ja not_active Expired - Fee Related
- 2002-02-22 AT AT02712105T patent/ATE307571T1/de not_active IP Right Cessation
- 2002-02-22 PL PL02365746A patent/PL365746A1/xx not_active Application Discontinuation
- 2002-02-22 NZ NZ527532A patent/NZ527532A/xx unknown
- 2002-02-22 IL IL15738902A patent/IL157389A0/xx unknown
- 2002-02-22 KR KR10-2003-7011178A patent/KR20030077042A/ko not_active Withdrawn
- 2002-02-22 WO PCT/GB2002/000766 patent/WO2002067893A2/en not_active Ceased
- 2002-02-22 HU HU0302847A patent/HUP0302847A3/hu unknown
- 2002-02-22 RU RU2003128971/15A patent/RU2003128971A/ru not_active Application Discontinuation
- 2002-02-22 EE EEP200300416A patent/EE200300416A/xx unknown
- 2002-02-22 SK SK1072-2003A patent/SK10722003A3/sk unknown
- 2002-02-22 US US10/468,276 patent/US20040067257A1/en not_active Abandoned
- 2002-02-26 UY UY27186A patent/UY27186A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100712A patent/AR032912A1/es not_active Application Discontinuation
2003
- 2003-08-15 IS IS6915A patent/IS6915A/is unknown
- 2003-08-26 NO NO20033785A patent/NO20033785L/no not_active Application Discontinuation
2004
- 2004-02-18 JP JP2004041583A patent/JP2004143185A/ja active Pending

Also Published As

Publication number	Publication date
CZ20032225A3 (cs)	2003-11-12
PL365746A1 (en)	2005-01-10
SK10722003A3 (sk)	2004-02-03
MXPA03007641A (es)	2003-12-04
JP2004521918A (ja)	2004-07-22
RU2003128971A (ru)	2005-03-10
CN1503662A (zh)	2004-06-09
WO2002067893A3 (en)	2003-01-16
HUP0302847A3 (en)	2005-05-30
AR032912A1 (es)	2003-12-03
JP3548566B2 (ja)	2004-07-28
NZ527532A (en)	2004-12-24
US20040067257A1 (en)	2004-04-08
EP1368001B1 (en)	2005-10-26
EP1368001A2 (en)	2003-12-10
DE60206889T2 (de)	2006-07-27
NO20033785L (no)	2003-10-24
JP2004143185A (ja)	2004-05-20
NO20033785D0 (no)	2003-08-26
HUP0302847A2 (hu)	2003-12-29
UY27186A1 (es)	2002-09-30
KR20030077042A (ko)	2003-09-29
WO2002067893A2 (en)	2002-09-06
ATE307571T1 (de)	2005-11-15
IS6915A (is)	2003-08-15
DE60206889D1 (de)	2005-12-01
EE200300416A (et)	2003-12-15
CA2439366A1 (en)	2002-09-06

Publication	Publication Date	Title
HUP0302847A3 (en)	2005-05-30	Pharmaceutical formulation comprising bicalutamide
GB0102342D0 (en)	2001-03-14	Pharmaceutical formulation
AU2002309172A1 (en)	2003-01-08	Pharmaceutical compositions containing polymer and drug assemblies
EP1367060A4 (en)	2004-04-14	GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en)	2004-05-06	GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en)	2004-04-14	GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
AU3085102A (en)	2002-06-24	Drug delivery compositions and medical devices containing block copolymer
PL370563A1 (en)	2005-05-30	Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
GB0118689D0 (en)	2001-09-19	Pharmaceutical formulation
HUP0302845A3 (en)	2005-11-28	4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
PL366432A1 (en)	2005-01-24	Pharmaceutical formulation
GB0322868D0 (en)	2003-10-29	A novel catalytic formulation and its preparation technical field
GB0108470D0 (en)	2001-05-23	Pharmaceutical compositions and their use
HUP0402318A3 (en)	2012-09-28	Pharmaceutical composition comprising cyclosporin and use thereof
EP1462455A4 (en)	2008-12-31	NOVEL PEPTIDES AND THEIR USES AS MEDICAMENTS
IL161902A0 (en)	2005-11-20	Pharmaceutical formulation comprising bicalutamide
IL161306A0 (en)	2004-09-27	Pharmaceutical formulation comprising (r)-bicalutamide
AU2002359618A1 (en)	2003-06-23	Medicinal compositions and therapeutic methods
PT1849468E (pt)	2013-02-27	Composição farmacêutica compreendendo roflumilaste levocetirizina
IL157451A0 (en)	2004-03-28	Medicinal compositions comprising diclofenac and ornoprostil
AU2002354070A1 (en)	2003-06-10	Medical polymers and use thereof
IL153176A (en)	2012-10-31	Phenylpiperazines and pharmaceutical compositions comprising them
GB0000482D0 (en)	2000-03-01	Enteric coated pharmaceutical formulation
GB0104749D0 (en)	2001-04-18	Pharmaceutical formulation
PL370709A1 (en)	2005-05-30	Pharmaceutical formulation comprising cyclosporin and use thereof